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Abstract
Background: The purpose of this study was to demonstrate the feasibility of physician driven planning in intensity
modulated radiotherapy (IMRT) with a multicriteria optimization (MCO) treatment planning system and template
based plan optimization. Exploiting the full planning potential of MCO navigation, this alternative planning approach
intends to improve planning efficiency and individual plan quality.
Methods: Planning was retrospectively performed on 12 brain tumor and 10 post-prostatectomy prostate patients
previously treated with MCO-IMRT. For each patient, physicians were provided with a template-based generated Pareto
surface of optimal plans to navigate, using the beam angles from the original clinical plans. We compared physician
generated plans to clinically delivered plans (created by dosimetrists) in terms of dosimetric differences, physician
preferences and planning times.
Results: Plan qualities were similar, however physician generated and clinical plans differed in the prioritization of
clinical goals. Physician derived prostate plans showed significantly better sparing of the high dose rectum and bladder
regions (p(D1) < 0.05; D1: dose received by 1% of the corresponding structure). Physicians’ brain tumor plans indicated
higher doses for targets and brainstem (p(D1) < 0.05). Within blinded plan comparisons physicians preferred the clinical
plans more often (brain: 6:3 out of 12, prostate: 2:6 out of 10) (not statistically significant). While times of physician
involvement were comparable for prostate planning, the new workflow reduced the average involved time for brain
cases by 30%. Planner times were reduced for all cases. Subjective benefits, such as a better understanding of planning
situations, were observed by clinicians through the insight into plan optimization and experiencing dosimetric trade-offs.
Conclusions: We introduce physician driven planning with MCO for brain and prostate tumors as a feasible planning
workflow. The proposed approach standardizes the planning process by utilizing site specific templates and integrates
physicians more tightly into treatment planning. Physicians’ navigated plan qualities were comparable to the clinical
plans. Given the reduction of planning time of the planner and the equal or lower planning time of physicians, this
approach has the potential to improve departmental efficiencies.
Keywords: IMRT, Multicriteria optimization, Efficiency, Physician IMRT planning
* Correspondence: birgit.mueller@tum.de
1Department of Radiation Oncology, Massachusetts General Hospital, Harvard
Medical School, Boston, MA, USA
2Department of Radiation Oncology, Klinikum rechts der Isar, Technical
University of Munich, Ismaninger Straße 22, 81675 Munich, Germany
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Müller et al. Radiation Oncology  (2017) 12:168 
DOI 10.1186/s13014-017-0903-z
Background
The creation of a radiotherapy treatment plan is a step-
wise process involving a diverse mix of staff. In clinical
practice treatment plans are usually generated by dosi-
metrists or medical physicists1, translating written clin-
ical prescriptions into dose distributions. The treatment
plan optimization is a multicriterial problem which leads
to inevitable trade-offs between targets and organs at
risk (OAR) such that not all clinical goals can always be
fulfilled [1–3]. Potential dosimetric conflicts might not
be obvious before the initiation of planning and thus
might not be addressed in the prescription. Clinical deci-
sions have to be made during planning as they arise.
Often planners1 spend much time trying to find a com-
promise between the different clinical goals, which
might not be the trade-offs most preferred by the phys-
ician. When plans are presented to the physicians for
clinical approval, it is often the first time the physician
has the opportunity to review the dose distribution and
many intermediate decision points with minimal or no
physician input may have been made.
Many physicians accept a plan if it fulfills the pre-
scribed dosimetric goals but it may not represent the
most suitable compromise between different objectives.
Being aware of the possibilities and weighing associated
clinical consequences physicians might select a different
trade-off. Making those clinical trade-off decisions
should ultimately be in the hands of the staff trained to
make them, i.e. the physicians.
Moreover, this current clinical planning practice fre-
quently results in iterative plan adaptations until the
plan is approved by the physician – a time consuming
process for both physician and planner.
In addition to the interaction between physicians and
planners for clinical decisions, the actual planning is fre-
quently inefficient. Planning is often a trial-and-error
process, with the quality of the final plan dependent on
the skills or personal perception of the planner. Planners
use different helper structures and parameters based on
experience and knowledge. Many attempts to standardize
treatment planning and improve its consistency by finding
class solutions and using knowledge based planning have
been reported [4–9].
Multicriteria optimization (MCO) has proven to be an
efficient treatment planning method, both in terms of
planning time and dosimetric quality [1, 10–12]. It is ap-
plicable to problems where there is no single clear optimal
solution, but instead the problem requires compromises.
These compromises are described mathematically on the
so-called Pareto surface of optimal plans [13, 14]. Plans on
the surface cannot be improved in one criterion without
worsening another [13, 15]. MCO planning software elim-
inates the time-consuming trial-and-error process of
selecting suitable weighting factors in conventional IMRT
planning [16–19] and visualizes these dosimetric trade-
offs. It provides a tool to interactively navigate on the sur-
face and investigate the trade-offs [16, 17] which makes
planning more intuitive but yet may not be fully exploited
in the current clinical planning routine.
One approach to make use of the MCO system, and to
improve treatment planning, both in achieving the desired
dosimetric goals and in increasing efficiency, is to involve
the physician at an earlier stage of the planning procedure.
We suggest physician driven planning as an alternative
planning procedure, which - similar to the current
workflow - consists of a collaboration of physicians and
planners, but differs in the order and responsibility of in-
volved tasks. Physician driven planning utilizing MCO
treatment planning software avoids the “human iteration
loop” between physicians and planners by providing
physicians the control over trade-offs, and allows them
to tailor the treatment plans to the individual patient.
In a retrospective planning study, we demonstrate the
feasibility of physician driven planning by template based
optimization and physician plan navigation as a suitable
planning procedure, and assess whether it has the poten-
tial to improve planning efficiency and quality. We com-
pare clinically delivered plans, created by dosimetrists,
to plans that physicians interactively navigated (Fig. 1).
Methods
The study is based on data from 12 brain tumor and 10
prostate cancer patients previously treated with MCO
optimized intensity modulated radiotherapy (IMRT) (step
and shoot) at Massachusetts General Hospital (MGH) and
selected randomly out of the clinical database.
Structure definition
Brain tumors
The patients featured a variety of diagnoses and intracra-
nial anatomical sites. The gross tumor volume (GTV) was
defined based on integrated CT and magnetic resonance
imaging from preoperative and postoperative studies.
Clinical target volumes (CTV) were created to encompass
additional regions of potential microscopic involvement.
Prescriptions to the planning target volume (PTV) (CTV
+ 3 mm) ranged from 36 Gy (12 × 3 Gy) to 60 Gy (30 ×
2 Gy). Standard OARs defined for all cases included the
brainstem, chiasm, optic nerves, eyes, lenses, lacrimal
glands, and cochleae. Tolerance doses varied dependent
on the individual case, i.e. tumor location and prescribed
dose. For 60 Gy commonly given constraints were
amongst others: maximum dose Dmax(optic nerves and
chiasm) < 54 Gy, Dmax(orbits) < 45 Gy, Dmax(brain-
stem) < 54 Gy in center, < 60 Gy on the surface, and a
maximum of 57 Gy to 5% of the volume.
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Prostate cancer
All cases had undergone radical prostatectomy and
were receiving postoperative radiation therapy. The
CTV (prostatic fossa), PTV, rectum, bladder (exclud-
ing CTV) and femoral heads were contoured for all
patients. Small bowel, sigmoid, residual seminal ves-
sels and penile bulb were added dependent on indi-
vidual patients’ anatomy and clinical situation. The
prescribed dose to the PTV (CTV + 8 mm, posterior: +
4 mm) was 66.6 Gy (37 × 1.8 Gy). For other planning pa-
rameters see Table 1.
MCO treatment planning
MCO-planning comprises the Pareto front calculation,
the subsequent plan navigation and deliverable plan
creation. The Pareto front is calculated by optimizing
various weighted sums of prior defined treatment ob-
jectives. For n objectives at least n + 1 plans are cal-
culated [15], and the maximum plan number is given
by the software with approximately 4n (default usage
for the study). Each treatment objective is represented
in the treatment planning system (TPS) navigation
interface by a slider (Fig. 2). It improves the corre-
sponding objective function and updates the dose dis-
tribution in real time when moved by interpolating
between pre-computed plans. After navigation, plans
are finalized by multileaf collimator (MLC) sequen-
cing and final dose calculation.
Clinical plans were generated in the commercial clinic-
ally implemented MCO-planning system RayStation (ver-
sion 4.0; RaySearch, Stockholm, Sweden); retrospective
physician driven plans were created in a research software
version (research version 4.4) (Fig. 1). Whereas plan navi-
gation in the commercial software is based on fluence
maps, the research module allows for navigation on seg-
mented plans which decreases dose differences of the final
planning step [20, 21] and may therefore be more suitable
for physician driven planning. With regards to all other
planning and dosimetric parameters, including the dose
calculation, the planning systems are identical.
Table 1 Typical MCO-problem formulations for prostate (prescription: 66.6 Gy); EUD: equivalent uniform dose [29], *excluding PTV wall
Constraints Objectives (slider)
PTV Min/ max dose = prescribed dose +/− 15% PTV 1) Min dose = prescribed dose
2) Max dose = prescribed dose
CTV Min DVH: prescribed dose to 95% volume CTV Min dose = prescribed dose
PTV wall (1 cm ring around PTV) Max dose = prescribed dose +3%
Rectum/ bladder (excluding CTV) Max dose = prescribed dose +5% Rectum/ bladder
(excluding CTV)
Dose-fall off: prescribed dose to 0 Gy in 1 cm
Normal tissue* Max dose = prescribed dose Normal tissue Dose-fall off: prescribed dose to 0 Gy in 1 cm
Femurs EUD, a = 2
Fig. 1 Planning study workflow
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Planning and optimization parameters
The clinically chosen beam settings were also used for
retrospective physician planning (prostate: 7 beams, brain
tumors: 4–7 beams) to ensure that all found dose differ-
ences between the clinically and physician generated plans
were the result of user preferences of plan nuances rather
than fundamental factors such as beam direction. The
clinical plans that served as our baseline comparison plans
were made by the clinical dosimetry treatment planning
staff who did not know that their plans would be used in a
retrospective comparison study. At MGH, treatment site
specific optimization templates exist and are recom-
mended for use. As planners often change these as they
wish, clinically utilized planning helper structures and
optimization parameters varied between planners and
patients. For the retrospective planning study a database
of Pareto optimal plans was created using mostly patient
independent but site specific, self-developed, templates
(Table 1) in order to test the idea that a template based
Pareto-surface creation technique was suitable for
physician-based MCO planning. The set of constraints
contained loose minimum and maximum doses to prevent
extreme under- and overdosage in the target and uncom-
promising doses to OARs, but not to restrain physicians
in their options. A detailed explanation of the imple-
mented objective functions can be found in [22].
Physician plan navigation
Physicians, who treated these patients before, were pro-
vided with the anonymized patients, the plan database
Fig. 2 Interface components of MCO-plan navigation: dose distributions are adjusted in real time by moving the sliders of different structures.
The dosimetric changes are also visualized in the dose volume histogram: current (straight line) and previous (dashed line) dose
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and patient information (prescription, constraints and
history); no access was given to the prior clinically
treated plan. Prostate plan navigation (Fig. 2) was con-
ducted with 9 sliders on average (max.10), brain tumor
cases with 15 (max. 16), amongst those a maximum of
three sliders for the target (two for the PTV, one for
CTV or GTV) (Table 1).
Plan evaluations and efficiency analysis
The final clinical and physician dose distributions were
analyzed by several dose volume histogram (DVH)
values. Statistical evaluations were performed by paired
t-tests and non-parametric signed rank tests. Two
weeks after planning physicians were asked for their
plan preference, for each patient case, in a blinded
comparison. Preferences were rated as slightly or sig-
nificantly different. The option “no preference” referred
to equal plan quality.
We analyzed required planning times of planners and
physicians for both procedures in a theoretical compari-
son of the main components, i.e. 1) beam selection (time
t1), 2) selection plus creation of helper structures for the
optimization (where applicable) and Pareto surface calcu-
lation (t2) and 3) navigation plus physician approval (t3).
Planners are involved in all steps (tplanner = t1 + t2 + t3,pl),
physicians exclusively in the last step (tph = t3,ph) (Fig. 3).
Physicians’ navigation times, including the deliverable plan
generation, were recorded, and clinical times were deter-
mined based on departmental interviews of staff members.
In clinical planning (CP), the required times are driven by
the number of iterations N between both staff members
until a plan is approved by the physician. Average phys-
ician and planner times t3,ph(CP) and t3,pl(CP) were calcu-
lated by the time to coordinate between physician and
planner, including the communication of new instruc-
tions, to review and approve the plan, multiplied by the
number of iterations of plan adaptations before approval.
Results
Dosimetric differences
Most evaluated criteria did not show significant differ-
ences or trends but were spread around zero, Dmean of
the femoral heads (Fig. 4a) being a typical example.
Prostate plans, generated by the physician, showed a bet-
ter sparing of high dose regions of bladder and rectum,
as demonstrated by the significant differences in
V65(rectum) (p = 0.009) and V65(bladder) (p = 0.003)
(relative volume receiving at least 65 Gy). The PTV
Fig. 3 Comparison of planning efficiency of current clinical planning versus physician driven planning of prostate (a) and brain tumor cases
(b). * refers to the selection and – where applicable - creation of helper structures for the optimization process
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covered by the 98%-isodose was significantly lower (V65
(PTV): p = 0.007) while the CTV received higher mean
doses. The trend of greater PTV-coverage in clinical
plans is presented in Fig. 4a by D95(PTV) (dose covering
95% of the PTV). One outlier did not follow this trend but
showed a low D95(PTV) (due to small bowel sparing). Ig-
noring this plan in the statistical evaluations would lead to
significance for D95(PTV) with p < 5% while the trend of
all other criteria would be the same.
Physician derived brain tumor plans indicated a trend
to higher doses in the targets and OARs, with a signifi-
cantly higher maximum dose to the brainstem
(D1(brainstem): p = 0.03) (Fig. 4b). Dose distributions of
one brain tumor and one prostate example showing
clear dosimetric differences are shown in Fig. 5.
Trade-off plots of different dosimetric objectives
present the chosen compromises by physicians and dosi-
metrists (Fig. 6). Except for the navigation to higher
CTV doses for a cost in increased D1(brainstem)
(Fig. 6b), no comprehensive trade-offs over all patients
were found for brain tumor plans; chosen compromises
differed between patients.
Physicians’ preferences
The blinded plan comparison results of physicians’ pref-
erence are presented in Table 2, which shows a slight
preference for the clinically generated plans. The doctors
decided all plans, whether selected or not, were clinically
acceptable. However, for one brain tumor case (Fig. 5)
the physician would have preferred to navigate again in
a
b
Fig. 4 a Normalized dose differences of prostate plans of performed t-tests; we also computed the non-parametric Wilcoxon signed rank p-
statistics since some of the difference data do not pass the Lilliefors normality test (due to the outliers). Those p-values lead to the same conclu-
sions as the p-values from the t-test. Starting with PTV D95, they are 0.08, 0.70, 0.03, 0.004, 0.04, 0.43, and 0.92. b Normalized dose differences of
brain tumor plans of performed t-tests; p-values of the Wilcoxon signed rank test, starting at PTV D95, are 0.97, 0.05, 0.23, 0.20, 0.019; remarks: CTV
refers to 11 CTVs and one GTV contour; brainstem statistics based on 11 contours
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Fig. 5 Case examples of remarkable differences between clinical and physician planning for brain tumor and prostate; blinded plan comparison
resulted in "no preference" for brain tumor (physician preferred an average of both) and in favor of physician prostate plan
a b
Fig. 6 Dosimetric trade-offs of selective DVH criteria for prostate (a) and brain tumor plans (b). Each data point represents the compromise
between two dosimetric objectives of one plan; physician (phys.) generated plan results are linked to corresponding clinical (clin.) plan trade-offs.
Nine prostate and 11 brain tumor cases are presented (excluding the prostate outlier, see Fig. 4a, and the brain case without brainstem contour).
(note: plans which are superior in all presented DVH criteria than the corresponding plan were worse in at least one other dosimetric objective
that is not included in the figure)
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order to achieve the average of the presented plans.
Prostate plans were additionally rated by a non-planning
involved physician who voted in favor of physician plans.
Physicians’ experiences
On a more qualitative basis, recorded physicians’ state-
ments during the sliding sessions, such as: “it is interest-
ing how this dose increases while the other one
decreases” or “that was a good deal” demonstrated the
physicians appreciating having the control over the dose.
Experiencing dosimetric trade-offs improved their com-
prehension of the planning situations.
Planning efficiency
Planners’ time
The first planning step, the beam selection, is identical
for both planning approaches (Fig. 3). In the second step
physician driven planning reduces planners’ time
through the utilization of pre-defined optimization tem-
plates, which can save up to Δt2 = 10 min, the approxi-
mate average time it takes to decide on objectives and
constraints and add them to the formulation. For step 3,
in clinical planning, the required number of iterations N
until a plan is approved (see above) is determined to be
N = 1 for prostate planning, as it is a standardized pro-
cedure and plans are mostly accepted at the first review.
For brain tumor cases N varies between one, two, and
occasionally three. We assume an average of N = 1.5 per
plan. Physician driven planning eliminates planners’
navigation completely which corresponds to a time of
approx. 10 min in simpler cases (see e.g. [1]) and up to
30 min in complex cases. Considering the factors of 1.0
and 1.5 (iterations), planner time Δt3,pl decreases by 10
and 45 min for prostate (Fig. 3a) and brain cases
(Fig. 3b), respectively.
Physician times
Clinical physician times to coordinate and communicate
with planners are on average 2 min for prostate and 5
min for brain cases. Plan review and approval take ap-
proximately 5 min for prostate and 10 min for brain
cases (complexity comparable to lung tumors, average
times published by [23]). Taking the number of
iterations into account, physician times were estimated
by 7 min for prostate (N = 1; tph(CP) = t3,ph(CP) ≅ 2 +
5 min) and 20–25 min for brain cases (N = 1.5;
tph(CP) = t3,ph(CP) ≅ 1.5 × 15 min).
Average physician navigation times were 10 min for
prostate and 16 min for brain tumor. Distinguishing
average times by the first and second half of navigated
plans, times decreased from 13 to 7 min (averages over
5 plans) and 17 to 15 min (averages over 6 plans) for
prostate and brain tumors, respectively.
The achieved physician time savings between both ap-
proaches were calculated by subtracting the average
navigation time (after more training) from the clinical
involvement times, which results in no time difference
for prostate (tph(PP) = t3,ph(PP) ≅ 7 min) (Fig. 3a) and
between 5 and 10 min for brain tumor cases
(tph(PP) = t3,ph(PP) ≅ 15 min) (Fig. 3b), corresponding to
a reduction of 30% of the involved time.
Discussion
We presented a planning approach with physician navi-
gation as a defining part of the process. While making
planning more patient independent by creating stan-
dardized databases, our approach makes it more individ-
ualized for each patient by not following the same
standard prescription for everyone but finding the best
trade-offs for every individual. This study sought to de-
termine if standardized MCO templates plus physician
navigation of the resulting Pareto surfaces could offer a
viable alternative to the standard planning process,
where tradeoffs are explored by the treatment planners
and the physicians are only involved in the final YES/
NO decision.
Our retrospective planning study is subject to limita-
tions given by inherent differences between clinical and
physician driven planning. Although clinical plans were
generated by different dosimetrists, they were regarded
as comparable. Different qualities within plans may have
resulted due to individual planning strategies and per-
sonal preferences. The utilization of different TPS soft-
ware versions may have led to a slight advantage in the
navigation process for physicians. As dosimetrists are
well trained to the clinical software version, and as the
intention of the study was not to compare minor but
Table 2 Physicians’ plan preferences: results of blinded plan comparison; *physician 1 = planning physician, physician 2 = a
non-planning involved physician
Brain tumors Prostate (physician 1*) Prostate (physician 2*)
Preference Degree Preference Degree Preference Degree
Physician generated plan 3 all slightly 2 1 slightly, 1 significantly 5 3 slightly, 2 significantly
Clinical plan 6 5 slightly, 1 significantly 6 4 slightly, 2 significantly 3 2 slightly, 1 significantly
No preference 3 – 2 – 2 –
Total 12 – 10 – 10 –
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rather fundamental dose differences, this difference is
assumed not to have an impact on the study results (for
details on dosimetric differences between the two soft-
ware versions see [21]). Further limitations are found in
the restricted number and variety of cases and of partici-
pating planning physicians (one for each case).
As the study was performed retrospectively, the exact
clinical planning times were not recorded, which prohib-
ited a plan by plan comparison of required times for
each step of the procedure. Instead we reverted to clin-
ical experiences of staff members and estimated average
times. Commonly, physician times are scarce due to
their clinical schedules, and the most expensive. This
motivates the aim to shorten physician involvement by
utilizing their time as best as possible. While for prostate
cases, required times to navigate were comparable to the
times to review and approve plans, physician driven
planning achieved sizeable time reductions for brain tu-
mors. Compared to prostate planning, these more com-
plex cases are usually subject to more dosimetric
conflicts and require more communication. Figure 5
presents a brain tumor case for which the physician pri-
oritized better target coverage over the hard constraint
on the brainstem. While dosimetrists usually respect for-
mulated hard constraints, physicians will not always ri-
gidly adhere to their standard prescriptions when
compromises are required. Not only in cases of incom-
patible goals but also when all constraints are achievable
simultaneously, physician background knowledge is im-
portant in order to decide how best to distribute or es-
calate the dose.
Contrary to possible expectations, the blinded com-
parison showed a slight preference (not statistically sig-
nificant) for the clinical plans for both physicians. In our
view, this reflects the fact that the treatment planners 1)
are experienced and 2) have effective working relation-
ships with the physicians such that they can achieve
plans deemed desirable by both physicians. In light of
these ideas, we find it encouraging from the perspectives
of increased throughput and increased physician involve-
ment that the plan quality of both planner and physician
generated plans are on par. Picking a preference between
two plan options was difficult. To examine whether the
preference decisions were stable, prostate plans were
rated by a second non-planning involved physician.
While the planning physician voted 2:6 for the physician
vs. the clinical plan (Table 2), the second doctor voted
5:3, favoring the physician plans. Both physicians chose
equally good twice but on different cases.
The choice of preferences demonstrated the inter-
observer variability [24] of opinions on plan quality.
Generally, plan preferences are considered to be caused
by personal clinical experiences, e.g. having recently ex-
perienced certain patient side-effects might lead to a
different point of view. Having a second physician re-
view the cases highlighted the result from the initial
physician selections that the two plans for each case are
both acceptable plans.
Due to the ongoing learning process of physicians
throughout the study, a final conclusion on physicians’
dose preferences might be too early and would require a
planning study with more physicians at a later stage of
MCO-training. This feasibility study was performed with
minimal trained physicians to demonstrate that physi-
cians can do plan navigation. Further improvements of
plan qualities are expected by improving optimization
formulations, e.g. by adapting objective functions and
structures to physicians’ needs instead of dictating them.
Generally, the choice of optimization parameters is
crucial. Translating physicians’ desires for each organ by
one slider is challenging and not always possible, given
that judging the dose distribution on even a single organ
is a multi-dimensional task [10]. In general it is difficult
to steer three dimensional dose distributions by using
one criterion, e.g. trying to get rid of a hot spot at a cer-
tain position might reduce dose of that structure at a
different location simultaneously. The development of
objective functions that allow for a more accurate and
specific steering and control of the doses could improve
planning in the future.
Our study provided insight into the planning process
to physicians with which they are often not familiar. In-
volving physicians is not only feasible but can also be
regarded as a gain of knowledge on more levels. Know-
ing the expense of a certain dosimetric goal like a homo-
geneous target dose distribution might change the
physicians’ point of view or expectations to a plan [25].
Even if clinical planning and navigation is not done by
the physicians it is a gain for the physician to understand
the process, and experience the trade-offs also for com-
prehending difficulties planners sometimes face.
MCO-treatment planning could also serve as a tool
for educational purposes and in clinicians’ rounds. Being
aware of realizable dose distributions, physicians could
better specify the prescriptions and clinical goals of each
individual case [26]. Clearer formulated prescriptions
will shorten the “back and forth” process between plan-
ner and physician and thus make the planning process
more efficient.
The suggested procedure may serve as a basis for a
discussion to refine optimal planning workflow. Obvi-
ously the planning cannot be done by physicians only, as
the whole plan creation would be too time consuming
for an efficient clinical workflow and best utilization of
clinician time. Here physicians were provided with the
prepared database, including prior required work steps
such as beam angle selections, and physician involve-
ment consisted of the final plan navigation and
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generation. The whole planning process is and will stay
an interactive process of a mix of professions. Our study
did not demonstrate the general superiority of this ap-
proach, but indicated that deviation from the standard
procedure has the potential to improve planning effi-
ciency, and possibly quality (physician navigation skills
improved over time). Finding the “best” approach to this
interactive process of different professions, in terms of
efficiency and resulting quality, still requires further
investigations.
It could be promising to combine MCO with knowledge-
based planning [7–9, 27, 28]. While automated knowledge-
based planning can generate good plans that are sometimes
even preferable to planner-generated IMRT plans, phy-
sicians still need to apply clinical judgment to make the
best treatment decision for each individual patient. In
our experience, the best way to accomplish this is
through the use of MCO – except for the most trivial
cases.
Knowledge based planning and MCO are both needed
and they are synergistic: the knowledge-based system
could provide the templates and beam orientations, as
well as the starting point for the interactive navigation.
The physician would then be involved in making rela-
tively minor adjustments using only a small number of
sliders/trade-offs, without being overwhelmed by too
many options.
We believe that planning systems of the future will be
both knowledge-based and MCO-based.
Conclusion
We demonstrated the feasibility of physician driven
planning in MCO treatment planning by Pareto surface
navigation on template based optimized plans. The plan
quality of physician generated plans was comparable to
the clinical plans with differences being observed due to
focusing on different clinical goals. This workflow always
reduces the required planner time while the reduction in
physician time is case dependent and potentially greater
for more complex cases. Although the evidence for
superior plan quality was not proven within this study,
and is certainly also case and patient dependent, it dem-
onstrated that increasing physician involvement and at
an earlier stage into the planning process is feasible and
has the potential to improve departmental efficiency.
Endnotes
1planning personnel varies between countries and clinics;
in the following “planner” refers to both professions.
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